• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Nonadherence Cost Pharma an Estimated $637 Billion in 2015, Says Report


November 16, 2016

In 2015 the pharma industry lost an estimated $637 billion due to nonadherence of medication for the treatment of chronic conditions, according to an updated research paper co-authored by HealthPrize Technologies and Capgemini.   Globally, the paper states, revenue loss has increased from $564 billion in 2012 to $637 billion in 2015, with US-based revenue losses increasing from $188 billion in 2012 to $250 billion in 2015.   "The tremendous human toll that results from nonadherence has been known for some time, but until we did the report with Capgemini, the business cost to the life science industry was not," said Tom Kottler, CEO of HealthPrize Technologies. "[W]e have shown that this business challenge continues to grow for pharmaceutical companies, while at the same time presenting them with their most significant opportunity to simultaneously support patients and shareholders."   Adherence564.com

Related Videos